RT Journal Article
T1 The role of CDK4/6 inhibitors in early breast cancer.
A1 Gil-Gil, Miguel
A1 Alba, Emilio
A1 Gavila, Joaquin
A1 de la Haba-Rodriguez, Juan
A1 Ciruelos, Eva
A1 Tolosa, Pablo
A1 Candini, Daniele
A1 Llombart-Cussac, Antonio
K1 Abemaciclib
K1 Adjuvant therapy
K1 Cyclin-dependent kinase 4/6 inhibitors
K1 Early breast cancer
K1 Palbociclib
AB The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), leading to a strong interest in their possible role in the treatment of early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the results of the large phase 3 adjuvant trials recently released, which have yielded apparently divergent results. We also examine the relevance of biomarkers as response predictive factors for CDI4/6i, the combination between radiotherapy and CDK4/6i, and provide a critical discussion on the evidence that we have so far and future directions of the role of these drugs in the treatment of early BC.
PB Churchill Livingstone
YR 2021
FD 2021-05-21
LK http://hdl.handle.net/10668/17956
UL http://hdl.handle.net/10668/17956
LA en
NO Gil-Gil M, Alba E, Gavilá J, de la Haba-Rodríguez J, Ciruelos E, Tolosa P, et al. The role of CDK4/6 inhibitors in early breast cancer. Breast. 2021 Aug;58:160-169
DS RISalud
RD Apr 5, 2025